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Abstract
Increased use of designer drugs (amphetamines and
amphetamine-like substances) raises the need for fast
screening tests in urine in clinical settings, workplace
and drug rehabilitation. Immunological assays cur-
rently used are subject to unwanted crossreactivities,
partly depending on the cutoff concentrations used.
The values recommended in Europe and the USA are
500 and 1000 ng/ml, respectively. In Switzerland, the
recommended concentration of 300 ng/ml results in a
high rate of false-positive urine samples and expen-
sive, time-consuming confirmation testing. Using the
Abbott Axsym analyzer, we found numerous false
positives from patients in rehabilitation centers due
to concomitant medication. Therefore, the diagnostic
sensitivity and specificity of the Abbott test at differ-
ent cutoff concentrations and the sensitivity of the
Roche Cobas Integra, Beckman Synchron and Biosite
Triage point-of-care test were examined. HPLC Bio-
Rad Remedi was chosen as the method of higher hier-
archical order. The specificity of the Axsym analyzer
(300 ng/ml) was 86%. At 500 ng/ml or 1000 ng/ml the
specificity was increased to 99 or 100%, respectively,
while the sensitivity only decreased from 97 to 91 or
81%, respectively. In summary, the cutoff concentra-
tion for amphetamine screening tests should not be
below 500 ng/ml to avoid a high rate of false-positive
results.
Keywords: amphetamine; Axsym; cutoff; HPLC;
screening test.
The abuse of amphetamine, methamphetamine and
other amphetamine-like substances (so-called design-
er drugs) has been increasing in Europe due to
increased sales and demand at popular rave parties.
Therefore, the rapid and inexpensive detection of
amphetamines and amphetamine-like substances in
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urine samples is important for physicians in emer-
gency rooms as well as for workplace testing and in
addiction rehabilitation clinics. In a clinical routine
laboratory, immunological techniques are the only
methods that can be used for the rapid detection of
amphetamine in urine samples. The cutoff values of
initial screening tests are currently under re-evalua-
tion in the United States. A lower cutoff concentration
of 500 ng/ml for screening of amphetamines in urine
has been proposed by the Substance Abuse andMen-
tal Health Services Administration (SAMHSA) (1),
while the cutoff value of 1000 ng/ml is currently used
for workplace drug testing (2). A cutoff concentration
of 500 ng/ml is recommended by the European Work-
place Drug Testing Society (EWDTS) (3). In this
regard, the Swiss working group for drugs of abuse
testing (AGSA) is recommending 300 ng/ml and
1000 ng/ml for addiction rehabilitation centers and
workplace testing, respectively, in its own guidelines
(4).
The immunoassays used for initial drugs of abuse
testing have to detect a wide variety of different
molecules (e.g., the amphetamine derivatives
methylenedioxymethamphetamine MDMA and
methylenedioxyamphetamine MDA) and are, there-
fore, subject to unwanted crossreactivities (e.g., with
different antidepressant and neuroleptic drugs).
Patients in addiction rehabilitation centers often have
prescriptions for many different psychoactive drugs.
Therefore, numerous false-positive results are expect-
ed. As a consequence, the high rate of positive urine
samples leads to expensive, time-consuming confir-
mation testing, which is not desirable and can cause
unnecessary confusion for patients and physicians.
In our laboratory many of the urine samples requir-
ing an amphetamine screening test are obtained from
addiction rehabilitation centers. Interestingly, we
found a surprisingly high number of positive tests for
amphetamine using the Axsym analyzer (Abbott, Illi-
nois, USA) that could not be confirmed by HPLC and
that were classified as false-positive results. The cut-
off value used was 300 ng/ml as recommended by the
Swiss AGSA. To clarify this issue, that very little infor-
mation can be found in the literature on sensitivity
and specificity, especially with respect to the different
cutoff values and methods (5–10), which stands in
striking contrast to the frequency of amphetamine
tests performed. We therefore decided to study the
diagnostic sensitivity and specificity of the fluores-
cence polarization immunoassay (FPIA) screening
test amphetamine/methamphetamine II (Axsym,
Abbott) at different cutoff levels (300, 500, 1000
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Table 1 Diagnostic specificity of the Axsym FPIA test at dif-
ferent cutoff levels and diagnostic sensitivity of the Axsym
FPIA at different cutoff levels, the Beckman Synchron, the
Roche Abuscreen online and the Triage tests.
Sensitivity, %
Cutoff level, ng/ml 300 500 1000
FPIA, Abbott Axsym 96.9 90.8 81.5
Synchron, Beckman – – 86.2
Abuscreen online, Roche – 93.9 –
Triage, Biosite – – 69.2
Specificity, %
Cutoff level, ng/ml 300 500 1000
FPIA, Abbott Axsym 86 99 100
Sensitivity was calculated using the following equation:
Screening test positives/HPLC positives wtrue positives/(true
positivesqfalse negatives)x. Specificity was determined as
follows: Screening test negatives/HPLC negatives wtrue neg-
atives/(true negativesqfalse positives).
ng/ml), as well as the diagnostic sensitivity of the FPIA
test in comparison with the Abuscreen online test
(Cobas Integra, Roche Diagnostics, Basel, Switzer-
land; cutoff value 500 ng/ml), the Synchron system
amphetamines test (Beckman-Coulter, Fullerton,
USA; cutoff value 1000 ng/ml) and the Triage point-
of-care test (Biosite, San Diego, USA; cutoff concen-
tration 1000 ng/ml). Detection of amphetamine and
amphetamine-like substances by HPLC on a Remedi
HS system (BioRad, Munich, Germany) was chosen
as a method of higher hierarchical order. The Remedi
HS system has been demonstrated to identify
amphetamines, methamphetamines and their deriv-
atives with a high degree of reliability (11, 12), allow-
ing its use as a confirmation method that is faster and
cheaper than gas chromatography-mass spectrome-
try. The cutoff concentrations for amphetamine and
amphetamine-like substances on the Remedi HS sys-
tem are 150 ng/ml for amphetamine and metham-
phetamine, and 100 ng/ml for MDA and MDMA,
respectively. Ten drug-free samples from healthy vol-
unteers, 65 samples positive for amphetamine as
determined by HPLC from confirmed users of
amphetamine and amphetamine-like drugs, and from
clinical routine, as well as 365 HPLC-negative urine
samples from routine testing were compared with all
screening methods. A higher number of positive sam-
ples would have been preferable. However, the ini-
tially determined analytical performance values
calculated with even fewer positive urine samples did
not significantly change upon inclusion of more
samples.
All drug-free samples from the healthy volunteers
tested negative with all methods. All HPLC-positive
urine samples were analyzed with the Axsym test
using different cutoff values as well as with the Abu-
screen online, Synchron and Triage point-of-care
assay. Consequently, the sensitivity was calculated
for all immunoassay tests (Table 1). Sensitivity was
defined as screening test positives divided by all
HPLC-positive samples. Three hundred and sixty five
HPLC-negative urine samples were analyzed with the
Abbott Axsym test using different cutoff concentra-
tions and the diagnostic specificity was calculated
(Table 1). None of the false-positive tests found with
the Axsym FPIA test could be reproduced with any
other immunoassay system tested. Of the urine sam-
ples tested false positive with the Axsym assay at cut-
off values of 300 or 500 mg/l, the following 11
non-amphetamine-like substances were found by
HPLC analysis: methadone, mianserine, bupivacaine,
domperidone, venlafaxine, monoacetylmorphine
(metabolite of heroin), fluoxetine, olanzapine, ateno-
lol, paroxetine and quinine. Of these compounds only
fluoxetine is known to cross-react with the Axsym
FPIA test. Therefore, drugs not detected by HPLC or
endogenous compounds may cause the false-positive
immunochemical findings as suggested by Schutz et
al. (13).
The positive urine samples, which have been con-
firmed by HPLC, contained amphetamine, metham-
phetamine and the amphetamine-like substances
MDA, MDMA, phenylpropanolamine and ephedrine
either alone or in different combinations.
Further, as shown in Table 1, increasing the cutoff
concentration of the FPIA Axsym test from 300 to
500 ng/ml led to a substantial increase in specificity
(q13%) and a smaller loss in sensitivity (y6%).
Increasing the cutoff value to 1000 ng/ml only slightly
increased the specificity (q1%), however, led to a
substantial decrease in sensitivity (y9%).
Most of the positive results using the FPIA Axsym
test at a cutoff concentration of 1000 ng/ml had mul-
tiples of cutoff of more than 2 (69%) or even more
than 8 (45%). Consequently, these strongly positive
results would not suggest a decrease in the cutoff val-
ue, resulting in even higher multiples of the cutoff.
The multiple of cutoff values of the positive Roche
Abuscreen tests are likewise high ()2 in 60%),
despite the fact that the cutoff concentration of the
Abuscreen test is already set at 500 ng/ml. In contrast,
only 19% of the positive samples have a multiple of
the cutoff)2 with the Beckman Synchron test. Unfor-
tunately, the results of this test are expressed in opti-
cal densities and not in concentrations. Therefore, the
determination of sensitivity and specificity using dif-
ferent cutoff values is not possible.
In conclusion, the recommended cutoff concentra-
tion for amphetamine screening tests in Switzerland
(300 ng/ml) is set far too low and only leads to a high
rate of false-positive results using the Axsym analyzer
or presumably any other screening test set at such a
low cutoff concentration. A cutoff value of 500 ng/ml
as recommended by the EWDTS is a reasonable com-
promise between good sensitivity and an acceptable
specificity. However, as currently no data are availa-
ble this applies to the Axsym FPIA test only. Data for
the diagnostic efficiency of the numerous other tests
that are on the market should be established and tak-
en into account before lowering the actual cutoff val-
ue of 1000 ng/ml recommended in the United States
(1). Finally, we found the diagnostic sensitivity of the
point-of-care device to be substantially lower than the
sensitivity of automated immunological tests. This is
in line with the higher threshold concentrations (fac-
tor 3–6) for different amphetamine derivatives of the
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Triage test compared to the FPIA test as described by
Felscher et al. (11). For this, whenever possible, auto-
mated quantitative immunoassays should be used.
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